Bronchonib 150 Soft Gelatin Capsule

Composition Nintedanib (150mg)
Rx Prescription Required
Pack strip of 10 capsules
Storage Store in a refrigerator (2 – 8°C). Do not freeze.
Chemical Class Indolecarboxylic Acids
Action Class Tyrosine Kinase Inhibitors (TKIs)
Habbit Forming
Manufacturer BDR Pharmaceuticals Internationals Pvt
Manufacturer address 407-408, Sharda Chambers, New Marine Lines, Mumbai 400 020 (Maharashtra), New Marine Lines, Marine Lines, Mumbai, Maharashtra 400020

Bronchonib 150 Soft Gelatin Capsule is used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer. It works by targeting certain pathways involved in the growth and progression of these diseases and helps to stop or slow the spread of cancer cells.

Bronchonib 150 Soft Gelatin Capsule should be taken with food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Diarrhea is a very common side effect of this medicine. You are advised to drink plenty of fluids and inform your doctor if it does not go away. Other common side effects include nausea, abdominal pain, vomiting, abnormal liver function tests, loss of appetite, headache, weight loss, and high blood pressure. Your doctor might ask you for some blood tests to monitor liver functioning.

Before taking it, tell your doctor if have a bleeding problem, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Treatment of Idiopathic pulmonary fibrosis

Treatment of Non-small cell lung cancer

Take this medicine in the dose and duration as advised by your doctor. Bronchonib 150 Soft Gelatin Capsule is to be taken with food.

Bronchonib 150 Soft Gelatin Capsule is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. It also blocks pathways in the body that result in fibrosis, which is the thickening or scarring of the tissue. This helps to stop or slow the spread of cancer cells.

Q: What if you forget to take Bronchonib Capsule?
A: If you miss a dose of Bronchonib 150 Soft Gelatin Capsule, skip it and continue with your normal schedule. Do not double the dose.

Bronchonib 150 Soft Gelatin Capsule is used for the treatment of thyroid cancer.

Take it with or without food, preferably at the same time each day.

Diarrhea may occur as a side effect. Drink plenty of fluids and inform your doctor if it doesn’t stop or if you find blood in your stools.

Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine and for a month after you stop taking it.

Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, confusion, problems with your eyesight, nausea or vomiting.

It may cause serious bleeding problem. Inform your doctor if you get headaches, stomach pain or if you notice blood in your urine or stools.

Do not take this medicine if you are pregnant, planning to conceive or breastfeeding.

In Treatment of Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a lung disease caused by lung tissue becoming thick and stiff and eventually forming scar tissue within the lungs. The scarring, or fibrosis, seems to result from a cycle of damage and healing that occurs in the lungs. These changes are irreversible and the affected person may experience shortness of breath or dry cough as initial symptoms. Bronchonib 150 Soft Gelatin Capsule kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. You may experience some bothersome side effects. Discuss with your doctor if you have any doubts.

Diarrhea

Nausea

Abdominal pain

Vomiting

Abnormal liver function tests

Loss of appetite

Headache

Weight loss

High blood pressure

Alcohol:CONSULT YOUR DOCTOR

It is not known whether it is safe to consume alcohol with Bronchonib 150 Soft Gelatin Capsule. Please consult your doctor.

Pregnancy:CONSULT YOUR DOCTOR

Bronchonib 150 Soft Gelatin Capsule is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.

Breast feeding:CONSULT YOUR DOCTOR

Bronchonib 150 Soft Gelatin Capsule is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Driving:UNSAFE

Bronchonib 150 Soft Gelatin Capsule may cause side effects which could affect your ability to drive.You may feel sick after taking this medicine and this could affect your driving.

Kidney:CAUTION

Bronchonib 150 Soft Gelatin Capsule should be used with caution in patients with severe kidney disease. Dose adjustment of Bronchonib 150 Soft Gelatin Capsule may be needed. Please consult your doctor.There is limited information available on the use of Bronchonib 150 Soft Gelatin Capsule in these patients.

Liver:CAUTION

Bronchonib 150 Soft Gelatin Capsule should be used with caution in patients with liver disease. Dose adjustment of Bronchonib 150 Soft Gelatin Capsule may be needed. Please consult your doctor.Use of Bronchonib 150 Soft Gelatin Capsule is not recommended in patients with moderate to severe liver disease.

Nintedanib. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc.; 2014. [Accessed 26 Mar. 2019] (online) Available from: View
Nintedanib esilate. Bracknell, Berkshire: Boehringer Ingelheim Limited; 2015 [revised 31 Oct. 2018]. [Accessed 26 Mar. 2019] (online) Available from: View
Central Drugs Standard Control Organisation (CDSCO). Nintedanib. [Accessed 26 Mar. 2019] (online) Available from: View